Search

Your search for "vtgn" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition

February 2, 2023

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions. Vistagen now owns all intellectual […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial

January 24, 2023

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that the first cohort of healthy volunteers has been dosed in its U.S. phase 1 clinical trial of PH10. The trial includes a newly optimized formulation […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter

January 19, 2023

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is preparing to launch a phase 1 trial of its novel pherine nasal spray for major depressive disorder (“MDD”). The company is anticipating that the trial, which […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial

January 10, 2023

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the last patient has completed the study protocol in its phase 2 clinical trial of PH94B for the treatment of adults experiencing […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program

January 3, 2023

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has recently filed national applications at the U.S. Patent and Trademark Office designed to provide additional patent protection for its lead product candidate, PH94B. The company has […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.

December 21, 2022

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Today Vistagen, together with Pherin Pharmaceuticals, a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment

December 6, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for the development of its proprietary investigational nasal spray: PH10. The designation can expedite […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101

November 17, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has published findings of a preclinical study of its oral NMDA receptor glycine site antagonist, AV-101. The positive findings evaluated the effects of AV-101 in a widely […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update

November 11, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results and corporate highlights for fiscal year 2023, the period ended Sept. 30, 2022. Among the highlights include news that an independent analysis […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast

November 4, 2022

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Nov. 10, 2022, to report financial results for […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference

November 3, 2022

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that its Chief Executive Officer Shawn Singh will present and host one-on-one meetings at the Stifel 2022 Healthcare Conference taking place in New York on Nov. […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Virtual Roundtable on Innovative Approaches to Mental Health Treatment

October 26, 2022

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the company’s Chief Executive Officer, Shawn Singh, will lead a Concordia Live Webinar on the need for innovative approaches to mental health treatment. According to […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment

October 20, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting on business conducted during its 2022 Annual Meeting of Stockholders. According to the announcement, the meeting was partially adjourned and will reconvene on Oct. 28, […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Shares Shareholder Voting Recommendations from Leading Proxy Advisory Firms

October 6, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that two leading independent proxy advisory firms have provided voting recommendations for upcoming annual meeting of stockholders. According to the announcement, the two firms — Institutional Shareholder […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference

October 3, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that its Chief Executive Officer Shawn Singh will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences

September 9, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that its Chief Executive Officer Shawn Singh will participate in two upcoming investor conferences in New York. VistaGen management will also be available […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Report FY 2023 Q1 Results, Host Conference Call and Webcast

September 8, 2022

VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on Thursday, Aug. 11, 2022, to report financial […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report

August 12, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss FY 2023 Q1 Financial Results

August 9, 2022

VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on Thursday, Aug. 11, 2022, to report financial […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B

July 22, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced topline results from its PALISADE-1 phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder. […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis

July 12, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, is slated to attend the upcoming Concordia Americas Summit. The 2022 Concordia Americas Summit is scheduled for July 13–14, 2022, in Miami as well as […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at William Blair Biotech Focus Conference 2022

July 7, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that its CEO Shawn Singh will participate in a panel discussing unmet needs and novel therapies in neuropsychiatry at the William Blair […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Corporate Update, FY 2022 Results

June 24, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today provided a corporate update and reported financial results for its fiscal year ended March 31, 2022. “Momentum from our accomplishments throughout our fiscal […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes PH94B PALISADE-1 Phase 3 Clinical Study for Acute Treatment of SAD

June 22, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that the last patient had completed the study protocol in its PALISADE-1 phase 3 clinical study. The study evaluated the potential for VTGN’s proprietary […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Webcast to Announce FY 2022 Results

June 17, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has scheduled a conference call and web cast to announce its fiscal year 2022 financial results. The event is slated for June 23, 2022, at […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting

June 2, 2022

VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that the clinical trial abstract for its exploratory phase 2A clinical study in adjustment disorder with anxiety (“AjDA”) for PH94B, its investigational […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences

May 27, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will present at two upcoming conferences scheduled in June. VistaGen CEO Shawn Singh will present at both the William Blair 42nd annual Growth Stock Conference […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer

May 2, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has announced its new chief legal officer: Reid Adler. According to the announcement, Adler’s new responsibilities will include overseeing the company’s legal affairs and providing […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses

April 21, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will be presenting its research at upcoming gatherings for two prestigious organizations. Company researchers will discuss preclinical data supporting the differentiated mechanism of action (“MOA”) […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial

April 12, 2022

VistaGen (NASDAQ: VTGN) and AffaMed Therapeutics have announced completion of regulatory preparations to initiate PALISADE Global, a phase 3 clinical trial to evaluate the efficacy, safety and tolerability of VistaGen’s PH94B (referred to by AffaMed as “AM005”) for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), in the U.S. and China. […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference

March 24, 2022

VistaGen (NASDAQ: VTGN), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer Shawn Singh will participate in a fireside chat with Maxim Analyst Jason McCarthy, Ph.D. The chat is slated to take […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update

February 11, 2022

VistaGen Therapeutics (NASDAQ: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system disorders, has reported its third-quarter 2022 financial and business status. Highlights of the report include the advancement of VTGN’s late-stage PH94B clinical program, including progress toward topline data readouts for phase […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call

February 7, 2022

VistaGen (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Thursday, […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18

November 16, 2021

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the company will participate in the upcoming Jefferies Virtual London Healthcare Conference. On Thursday, November 18, VistaGen’s Chief Executive Officer Shawn […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights

November 11, 2021

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its second-quarter 2022 financial and business status. Highlights of the reports include that progress on […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update

November 4, 2021

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has scheduled a Nov. 10, 2021, conference call and webcast. During the call, which is slated to […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial

October 14, 2021

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of a phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity

October 5, 2021

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has released data regarding a new mechanism of action. The data was gathered from a preclinical tissue distribution study studying laboratory rats […]

InvestorNewsBreaks

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Further Advancement of PALISADE Program for PH94B in Social Anxiety Disorder

September 13, 2021

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of PH94B for the […]

InvestorNewsBreaks

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Baird Global Healthcare Conference

September 8, 2021

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be featured in the upcoming Baird’s 2021 Global Healthcare Conference. VistaGen management, including VistaGen CEO Shawn […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).